My name is Dr. Thomas J, Coates and I
serve as a Professor of Infectious Diseases at the David Geffen School of
Medicine at the University of California, Los Angeles. I am also the Director of the UCLA Program
in Global Health, and have ongoing research among gay men in the US, and among
a variety of populations in Central and Southern Africa, Latin America, and
China. I have been working in HIV
prevention research since 1983, and one of my focus areas has been HIV
counseling and testing. I published some
of the earliest studies on this topic from San Francisco and Africa, and have
continued to conduct research on this topic.
The following thoughts are offered in
response to the FDA announcement seeking public commentary in relation to the
over-the-counter availability of rapid HIV testing. For the purposes of reaching a broader audience whom we hope
will engage in this discussion, it will be useful to review the most recent
data on HIV in order to make an informed decision on whether to permit HIV
rapid testing over the counter.
Twenty-four years after the first diagnosis, gay
men are still infected the most, but it's rising fastest in African-Americans
and other minorities. African-Americans
are about 12 percent of the population, but about 50 percent of the AIDS cases.
Hispanics are about -- 14 percent of the population, about 20 percent of the
AIDS cases. It is also important to
note that HIV has become more feminine, about 27 percent of cases are now women.
Data suggests that new hopes in AIDS treatments
have overshadowed the fact that the virus continues to spread, and AIDS is
increasingly an epidemic of teenagers and young adults in America. For perspective, every hour, two Americans
under the age of 25 become infected with HIV; and every minute, 50 young
Americans contract a sexually transmitted disease. We should be encouraged by the fact that people are living longer
now, and when the new treatment was were first introduced, we weren't sure how long
it was going to last and how long it was going to be beneficial. That said, while research has delivered
exceptional HIV treatments, continued enhancements in therapies is also
critical.
There are nearly 40,000 new infections each year in
United States, bringing the total number of persons living with HIV to more
than one million. Perhaps most
troubling is the fact that an estimated quarter of these individuals don't even
know they are infected, and could be passing on the virus. This is why proven prevention strategies,
including regular and routine HIV screening across all public health settings,
including emergency rooms, labor and delivery, and broader use of new rapid
testing technologies remains critical.
With respect to the question at hand, studies
clearly demonstrate that once a person is aware of their status, if positive,
they are up to 70% less likely to engage in behaviors that will place
themselves and others in jeopardy. We
also know, from numerous studies, that choice helps people engage in
prevention. More choice translates into
a greater likelihood that people will find a strategy acceptable to them.
With regard to HIV testing, this means making
testing available in a variety of ways and in a variety of formats. Right now, in the US, most HIV testing
occurs in doctor’s offices. Some occurs
in anonymous of confidential testing sites, or in STD clinics or drug treatment
programs. Testing also occurs in
pre-natal clinics and hospitals with high prevalence of HIV. These offer many ways for people to get
tested—with or without counseling, anonymous of confidentially, in an opt-in or
opt-out framework, when they are needing it the most (with symptoms of an STD
or neding drug treatment).
Offering over the counter testing is another
excellent way to make testing available to people. Concerns have been raised that people need counseling. Mot people now accessing testing do not get
counseling. Concerns are also raised
that people cannot handle the information.
That concern has been raised from the beginning of HIV testing, and the
casualties are few and far between.
While the news of an HIV diagnosis is not great, it’s also not the end
of the world and most people know that and can handle the information. In fact, with advances in treatment, HIV can
be a chronic manageable disease.
Further, we need to normalize HIV, and it is time to realize that people
can handle the news of an HIV diagnosis just like they can handle the news of
pregnancy and other issues like that.
Therefore, I support making the new FDA approved rapid
saliva test available over the counter.
It offers the possibility of expanding the reach of HIV screening in
ways previously unavailable.
Thank you for fostering this dialogue
and I ask that a copy of my remarks be placed in the record. Also, for the record, I receive no support
from any pharmaceutical or diagnostic manufacturer. My work is totally supported by private donations, NIH funding,
and foundations.